Clinical trial · Interventional
Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma
Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Open-label, multicenter, single arm phase II study, set up in collaboration with the "Réseau d'Expertise Français sur les Cancers ORL Rares" (REFCOR), evaluating the activity and safety of single agent pazopanib in recurrent or metastatic tumors in salivary gland including adenoid cystic carcinoma (ACC) and to exploring the activity and safety of pazopanib in non-adenoid cystic carcinoma (non-ACC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Salivary Gland Carcinoma | Salivary Gland Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pazopanib | Drug | Pazopanib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- pazopanib
- description
- Pazopanib per os, 800mg daily until progression
- interventionNames
- Drug: pazopanib
Primary outcomes (1)
- measure
- progression free survival
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed diagnosis of recurrent and/or metastatic salivary glands (including ACC and non ACC). * Progressive disease within 6 months before inclusion as assessed by CT and/or MRI using at least two measurements (RECIST v1.0) with at least one measurable target lesion \>10 mm. * Recurrent and/or metastatic salivary glands carcinoma failing locoregional therapy, without possibility of curative treatment. * Patients may have had unlimited prior therapy but must have had at least 4 weeks between any chemotherapy, radiotherapy, surgery and study enrollment. * Tumoral tissue must be provided for subsequent histological review and biomarker analysis. * Euthyroid patient. * Hepatic, renal, cardiac and hematology normal functions. * Ability to take oral medication. Exclusion Criteria: * Non salivary gland carcinoma (lachrymal gland tumor is excluded). * Known or symptomatic cerebral metastasis. * Patients treated with strong inhibitor or inductor of CYP3A4 within 14 days before inclusion. * Presence of uncontrolled infection. * Diagnosis of any previous malignancy within the last 5 years, except for completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma. * Stable disease. * Corrected QT interval (QTc) \>480 msecs using Bazett's formula.
References
Publications (0)
Data not yet available